

Addressing Unmet Patient Needs in Bullous Pemphigoid

Exploring Targeted Treatment for Safe and Effective Care

Activity Description

Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease and occurs most frequently in elderly patients, with risk rising exponentially after the age of 80. However, diagnosis is often missed or delayed, partly due to clinicians' lack of familiarity with the condition and partly due to atypical presentation. Systemic corticosteroids are the mainstay of treatment but are associated with considerable adverse events, particularly in the elderly population. Thus, targeted agents that are already approved for other diseases are now under study for their utility in BP as safer and more effective options. This program will provide learners with expert guidance regarding the recognition and diagnosis of BP, the impact of BP on elderly patients, and the latest evidence with regard to the use of targeted agents and the clinical implications should these agents be approved.

Target Audience

This activity has been designed to meet the educational needs of dermatologists, dermatology advanced practice providers, and other clinicians who care for patients with bullous pemphigoid.

Educational Objectives

Upon completion of this activity, participants should be better able to:

- Identify and differentiate bullous pemphigoid (BP) from other skin conditions that can present similarly, based on current guidelines and expert recommendations
- Discuss the impact of BP on elderly patients with regard to morbidity/mortality and quality of life, particularly for those with several comorbidities
- Select and monitor treatment for patients with BP according to updated guidelines
- Explain the rationale to improve outcomes for patients with BP through the use of targeted therapy

Method of Participation


There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Accreditation, Support, and Credit

 In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

 Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

PeerView
Live

This CME/MOC/NCPD/AAPA activity is provided by PVI, PeerView Institute for Medical Education. This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.



[PeerView.com/BP-Survey-MPM](https://www.peerview.com/BP-Survey-MPM)

Addressing Unmet Patient Needs in Bullous Pemphigoid

Exploring Targeted Treatment for Safe and Effective Care

Physician Assistants



PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to *The Standards for Integrity and Independence in Accredited Continuing Education*. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. **All relevant conflicts of interest have been mitigated prior to the commencement of the activity.**

Co-Chair/Planner

Erin X. Barrett (Wei), MD
Associate Professor of Dermatology
University of Nebraska Medical Center/Nebraska Medicine
Co-Director of the Bullous Disease Clinic
Director of Clinical Trials
Director of Inpatient Dermatology Services
Director of the Skin of Color/Ethnic Skin Dermatology Clinic
Omaha, Nebraska

Erin X. Barrett (Wei), MD, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner

David Rosmarin, MD
Chair, Kampen-Norins Scholar
Indiana University
Indianapolis, Indiana

David Rosmarin, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Inc.; Abcuro, Inc.; AltruBio, Inc.; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Concert Pharmaceuticals, Inc.; CSL; Dermavant Sciences, Inc.; Dermira, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Kyowa Kirin Co., Ltd.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Recludix; Revolo Biotherapeutics; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries, Ltd.; UCB; and Viela Bio, Inc.

Grant/Research Support from AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Celgene Corporation; Dermira, Inc.; Galderma S.A.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.
Speaker for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Celgene Corporation; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.

Honoraria from AbbVie Inc.; Abcuro, Inc.; AltruBio, Inc.; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Concert Pharmaceuticals, Inc.; CSL; Dermavant Sciences, Inc.; Dermira, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Kyowa Kirin Co., Ltd.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Recludix; Revolo Biotherapeutics; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries, Ltd.; UCB; and Viela Bio, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

PeerView
Live

This CME/MOC/NCPD/AAPA activity is provided by PVI, PeerView Institute for Medical Education. This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.



[PeerView.com/BP-Survey-MPM](https://www.peerview.com/BP-Survey-MPM)